Stockscreener 앱 받기
7.215
0.49%
0.035
시간 외 거래:
7.21
-0.005
-0.07%
전일 마감가:
$7.18
열려 있는:
$7.04
하루 거래량:
148.82K
Relative Volume:
0.36
시가총액:
$483.33M
수익:
-
순이익/손실:
$-122.44M
주가수익비율:
-3.201
EPS:
-2.254
순현금흐름:
$-103.79M
1주 성능:
-1.16%
1개월 성능:
-32.06%
6개월 성능:
+5.79%
1년 성능:
+33.61%
1일 변동 폭
$6.95
$7.24
1주일 범위
$6.9101
$7.92
52주 변동 폭
$2.65
$12.25
Engene Holdings Inc Stock (ENGN) Company Profile
명칭
Engene Holdings Inc
전화
(514) 332-4888
주소
4868 RUE LEVY, SUITE 220, SAINT-LAURENT
Compare ENGN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENGN
Engene Holdings Inc
|
7.215 | 480.98M | 0 | -122.44M | -103.79M | -2.254 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Engene Holdings Inc Stock (ENGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-30 | 개시 | Jefferies | Buy |
| 2025-11-11 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2025-02-18 | 개시 | Piper Sandler | Overweight |
| 2025-02-14 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-12-23 | 개시 | H.C. Wainwright | Buy |
| 2024-11-27 | 개시 | Raymond James | Outperform |
| 2024-11-18 | 개시 | JMP Securities | Mkt Outperform |
| 2024-08-28 | 개시 | Oppenheimer | Outperform |
| 2024-04-22 | 개시 | Wells Fargo | Overweight |
| 2024-04-15 | 개시 | Guggenheim | Buy |
| 2024-03-28 | 개시 | UBS | Buy |
| 2024-03-08 | 개시 | Morgan Stanley | Overweight |
| 2024-02-20 | 개시 | Leerink Partners | Outperform |
모두보기
Engene Holdings Inc 주식(ENGN)의 최신 뉴스
Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care - The Globe and Mail
enGene CEO Pitches Detalimogene as Community-Friendly NMIBC Option, Teases Q2 LEGEND Data Update - MarketBeat
enGene Shares Detalimogene NMIBC Trial Changes, FDA Endpoint Shift, and 2027 Approval Path at Conference - MarketBeat
Portfolio Update: Is enGene Holdings Inc stock a good dividend stock2026 Performance Recap & Community Trade Idea Sharing Platform - baoquankhu1.vn
Aug Reactions: Why is enGene Holdings Inc Equity Warrant stock going up2026 EndofYear Setup & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Short Interest in enGene Holdings Inc. (NASDAQ:ENGN) Decreases By 17.7% - MarketBeat
enGene Highlights 2026 Data Catalysts, BLA Plans for Bladder Cancer Gene Therapy at Barclays Conference - MarketBeat
Braidwell LP Invests $15.48 Million in enGene Holdings Inc. $ENGN - MarketBeat
enGene (NASDAQ:ENGN) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Oppenheimer Issues Pessimistic Forecast for enGene (NASDAQ:ENGN) Stock Price - Defense World
Merger Talk: Can enGene Holdings Inc Equity Warrant lead its sector in growth2026 Key Highlights & Reliable Price Action Trade Plans - baoquankhu1.vn
AI Stocks: Will enGene Holdings Inc stock benefit from M A2026 Short Interest & Entry and Exit Point Strategies - baoquankhu1.vn
enGene Holdings: Key Catalysts Incoming For 2026 (NASDAQ:ENGN) - Seeking Alpha
enGene (NASDAQ:ENGN) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat
Citizens reiterates Engene Holdings stock rating on BLA timeline By Investing.com - Investing.com South Africa
HC Wainwright Has Optimistic Outlook of enGene Q2 Earnings - MarketBeat
Citizens reiterates Engene Holdings stock rating on BLA timeline - Investing.com
FY2030 Earnings Forecast for enGene Issued By HC Wainwright - Defense World
enGene Shares Gain 5% After Bladder Cancer Therapy Shows Stronger Response Rates - MSN
enGene (NASDAQ:ENGN) Price Target Lowered to $30.00 at Oppenheimer - MarketBeat
Pullback Watch: How does enGene Holdings Inc compare to its peers2026 Highlights & Weekly High Return Opportunities - baoquankhu1.vn
ENGN: Detalimogene offers promising efficacy and convenience for NMIBC, with pivotal data updates ahead - TradingView
HC Wainwright Has Positive Outlook of enGene FY2030 Earnings - MarketBeat
enGene Holdings (ENGN) Gets a Buy from Wells Fargo - The Globe and Mail
Smart Money: Can SIFCO Industries Inc continue delivering strong returns2026 Momentum & Stepwise Trade Signal Guides - baoquankhu1.vn
ENGN: Detalimogene's pivotal data and unique profile position it to transform NMIBC treatment - TradingView
enGene (NASDAQ:ENGN) Posts Earnings Results, Beats Estimates By $0.11 EPS - MarketBeat
ENGN: Detalimogene offers a unique, highly tolerable NMIBC therapy with pivotal data updates in 2024 - TradingView
Engene stock price target lowered to $27 by Guggenheim on estimates By Investing.com - Investing.com India
Engene stock price target lowered to $27 by Guggenheim on estimates - Investing.com Australia
Raymond James Maintains Strong Buy on ENGN enGene Holdings Inc March 2026 - Meyka
enGene Holdings Inc. Q1 2026 Quarterly Report: Financial Statements, Management Discussion & Key Disclosures - Minichart
enGene Reports Q1 2026 Results, Advances Detalimogene for Bladder Cancer with Strong Cash Position and FDA Milestones 12 - Minichart
enGene Holdings Inc. Announces Sales Agreement with Leerink Partners LLC for At-the-Market Offering of Common Shares - Minichart
enGene (NASDAQ:ENGN) Shares Gap DownHere's Why - MarketBeat
Raymond James reiterates Engene Holdings stock Strong Buy rating By Investing.com - Investing.com South Africa
HC Wainwright Reiterates 'Buy' Rating for enGene Holdings (ENGN) - GuruFocus
enGene's (ENGN) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Raymond James reiterates Engene Holdings stock Strong Buy rating - Investing.com
enGene Reports First Quarter 2026 Financial Results and Provides Business Update - BioSpace
enGene Holdings Inc reports results for the quarter ended January 31Earnings Summary - TradingView
ENGN: Protocol changes and strong regulatory support position the product for broad community adoption - TradingView
ENGN: Holistic protocol changes and regulatory support position the program for a strong commercial launch - TradingView
Junshi Biosciences Announces NMPA Acceptance of New Drug Applications for Toripalimab Injection (Subcutaneous) Across 12 Indications - GlobeNewswire Inc.
enGene Strengthens Balance Sheet as Bladder Cancer Gene Therapy Nears Key 2026 Milestones - TipRanks
enGene Holdings Inc. (NASDAQ: ENGN) launches $100M ATM share program with Leerink - Stock Titan
Form 424B5 enGene Holdings Inc. - StreetInsider
Engene Holdings Enters Sales Agreement With Leerink Partners To Sell Common Shares - TradingView
enGene Holdings (NASDAQ: ENGN) launches $100M ATM and ends Jefferies deal - Stock Titan
enGene Holdings 10-Q: $0 Revenue, $0.44 Loss Per Share on $29.8M Net Loss - TradingView
enGene (NASDAQ: ENGN) details Q1 loss, LEGEND trial data and cash runway - Stock Titan
Engene Holdings Inc (ENGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):